Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413254 | 0.86 | LMNA (0.81) | LMNAALOX15PTPN7MAPK1PPARG | |
| SCHEMBL655613 | 0.85 | CYP3A4 (0.56) | LMNATP53CYP3A4MAOBTSHR | |
| SCHEMBL10753958 | 0.84 | CYP3A4 (0.59) | LMNATP53CYP3A4MAOBTSHR | |
| SCHEMBL6538768 | 0.81 | PTGDR2 (0.59) | LMNAALOX15PTPN7PTGDR2DHFR | |
| SCHEMBL217079 | 0.81 | CYP3A4 (0.56) | LMNATP53CYP3A4MAOBTSHR | |
| SCHEMBL6309076 | 0.81 | CYP3A4 (0.61) | LMNATP53CYP3A4MAOBPPARG | |
| SCHEMBL5120648 | 0.81 | MAPK1 (0.64) | LMNAALOX15TP53PTPN7MAPK1 | |
| SCHEMBL3924075 | 0.80 | ALOX15 (0.54) | LMNAALOX15PTPN7PTGDR2TSHR | |
| SCHEMBL1018491 | 0.80 | KMT2A (0.54) | LMNATP53CYP3A4MAOBTSHR | |
| SCHEMBL3651443 | 0.80 | TP53 (0.59) | LMNATP53CYP3A4MAOBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| US-9714238-B2 | Therapeutic agents for ocular hypertension | ALLERGAN, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160340347-A9 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2016-11-24 | — | — | US | disclosed |
| US-20150175586-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| EP-2844638-A1 | NOVEL EP2 RECEPTOR AGONISTS | Takeda GmbH (DE) | 2015-03-11 | — | — | EP | disclosed |
| EP-1663204-B1 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-1663204-B1 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8710222-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710222-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-1123283-A1 | THIAZOLE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000024724-A1 | THIAZOLE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-04 | — | — | WO | disclosed |
| US-5776929-A | GASTRIN INHIBITOR; GASTROINTESTINAL DISORDERS | SHIONOGI & CO., LTD. (JP) | 1998-07-07 | — | — | US | disclosed |
| EP-0728748-A1 | NOVEL BENZODIAZEPINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1996-08-28 | — | — | EP | disclosed |
| US-5382590-A | Gastrointestinal disorders and nervous system disorders | RHONE-POULENC RORER S.A. (FR) | 1995-01-17 | — | — | US | disclosed |
| EP-0230985-B1 | GAMMA-GLUTAMYL-4-AZOANILIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE DETERMINATION OF GAMMA-GLUTAMYLTRANSFERASE | Roche Diagnostics GmbH (DE) | 1990-08-01 | — | — | EP | disclosed |
| US-4943526-A | LIVER DISORDERS, DETERMINATION OF GAMMA GLUTAMYL TRANSFERASE | BOEHRINGER MANNHEIM GMBH (DE) | 1990-07-24 | — | — | US | disclosed |
| US-4769447-A | SUBSTRATES FOR G-GLUTAMYL TRANSFERASE DETERMINATION | BOEHRINGER MANNHEIM GMBH (DE) | 1988-09-06 | — | — | US | disclosed |
| EP-0230985-A2 | Gamma-glutamyl-4-azoanilides, process for their preparation and their use for the determination of gamma-glutamyltransferase | Roche Diagnostics GmbH (DE) | 1987-08-05 | — | — | EP | disclosed |
| US-3932122-A | COLORING POLYESTER TEXTILES | CIBA-GEIGY AG (CH) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175586-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | LMNA 1956/4885ALOX15 1315/4885TP53 4243/4885 |
| US-20160340347-A9 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | LMNA 1956/4885ALOX15 1315/4885TP53 4243/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | LMNA 4489/4885ALOX15 4806/4885TP53 436/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | LMNA 2409/4885ALOX15 979/4885TP53 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.